CN110799212A - 特异性存在于调节性t细胞中的dkk1蛋白及其用途 - Google Patents

特异性存在于调节性t细胞中的dkk1蛋白及其用途 Download PDF

Info

Publication number
CN110799212A
CN110799212A CN201880031227.9A CN201880031227A CN110799212A CN 110799212 A CN110799212 A CN 110799212A CN 201880031227 A CN201880031227 A CN 201880031227A CN 110799212 A CN110799212 A CN 110799212A
Authority
CN
China
Prior art keywords
immune
epitope
dkk1
cells
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880031227.9A
Other languages
English (en)
Chinese (zh)
Inventor
金廷镐
金范锡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Goodall T Cell Co Ltd
Good T Cells Inc
Original Assignee
Goodall T Cell Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goodall T Cell Co Ltd filed Critical Goodall T Cell Co Ltd
Publication of CN110799212A publication Critical patent/CN110799212A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201880031227.9A 2017-05-10 2018-05-10 特异性存在于调节性t细胞中的dkk1蛋白及其用途 Pending CN110799212A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2017-0058336 2017-05-10
KR10-2017-0058337 2017-05-10
KR20170058336 2017-05-10
KR20170058337 2017-05-10
PCT/KR2018/005398 WO2018208108A1 (fr) 2017-05-10 2018-05-10 Protéine dkk1 présente spécifiquement dans des lymphocytes t régulateurs et son utilisation

Publications (1)

Publication Number Publication Date
CN110799212A true CN110799212A (zh) 2020-02-14

Family

ID=64105283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880031227.9A Pending CN110799212A (zh) 2017-05-10 2018-05-10 特异性存在于调节性t细胞中的dkk1蛋白及其用途

Country Status (4)

Country Link
JP (1) JP2020519268A (fr)
KR (1) KR20180123989A (fr)
CN (1) CN110799212A (fr)
WO (1) WO2018208108A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3913055A4 (fr) * 2019-01-15 2023-09-27 Bioneer Corporation Oligonucléotide double brin ciblant le gène dkk1, construction comprenant cet oligonucléotide et composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux contenant cette construction
US20220213186A1 (en) * 2019-03-20 2022-07-07 Good T Cells, Inc. Composition for preventing or treating brain and nervous system disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1

Also Published As

Publication number Publication date
WO2018208108A1 (fr) 2018-11-15
JP2020519268A (ja) 2020-07-02
KR20180123989A (ko) 2018-11-20

Similar Documents

Publication Publication Date Title
US7198899B2 (en) Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
AU2005265067B2 (en) Combination of a chemotherapeutic agent and an antagonist of a gene product for treating tumors
US7815906B2 (en) Compositions and methods for restoring sensitivity to treatment with HER2 antagonists
EP2556091B1 (fr) Anticorps reconnaissant le facteur d'inhibition de la leucémie humaine (LIF) et utilisation d'anticorps anti-LIF pour le traitement de maladies associées à la prolifération de cellules indésirables
US20210095044A1 (en) Motile sperm domain containing protein 2 and cancer
KR20080059449A (ko) 치료용 약제
CN112672760A (zh) 新颖lilrb4抗体和其用途
EP3371216B1 (fr) Anticorps humanisés anti-bag3
KR20120120193A (ko) T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법
EP4056586A1 (fr) Épitope d'antigène de surface de lymphocyte t régulateur, et anticorps se liant de manière spécifique à celui-ci
JP2024010054A (ja) ヒトがんの治療のためのモノクローナル抗体neo-201
CN110799212A (zh) 特异性存在于调节性t细胞中的dkk1蛋白及其用途
US20080267951A1 (en) Methods for Treating Cancer Using Agents That Inhibit Wnt16 Signaling
WO2019158512A1 (fr) Méthodes pour le pronostic et le traitement du glioblastome
WO2009044158A2 (fr) Inhibiteurs et utilisations
US7227007B2 (en) NF-κB activating gene
WO2018046770A2 (fr) Marqueur et cible en tant que variable de diagnostic et cible pour le traitement du cancer métastatique
EP3798227A1 (fr) Épitope d'antigène de surface de lymphocyte t régulateur et anticorps se liant de manière spécifique à celui-ci
US20200024347A1 (en) Or10h1 antigen binding proteins and uses thereof
EP4219550A1 (fr) Anticorps monoclonaux contre l'eltd1 et leurs utilisations
WO2022081869A1 (fr) Compositions et procédés pour surmonter une évasion immunitaire induite par dr5 par des tumeurs solides
EP3256148A1 (fr) Procédés pour prédire la réactivité d'un patient atteint d'une maladie hématologique maligne à un traitement par chimiothérapie et procédés de traitement de ces maladies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200214